ZSAN · Zosano Pharma Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $132.0K | - | $252.0K | $0 | $0 | - | $0 | $0 | $0 | - |
| Cost of Revenue | $86.0K | - | $340.0K | $0 | $0 | - | - | - | - | - |
| Gross Profit | $46.0K | - | ($88.0K) | $0 | $0 | - | - | - | - | - |
| R&D | $4.48M | - | $5.99M | $5.00M | $5.33M | - | $5.82M | $4.93M | $5.51M | - |
| SG&A | $2.94M | - | $2.52M | $2.96M | $2.81M | - | $2.70M | $2.77M | $3.08M | - |
| Total Operating Expenses | $33.45M | - | $8.85M | $7.70M | $8.60M | - | $8.53M | $7.70M | $8.60M | - |
| D&A | $250.0K | - | $500.0K | $300.0K | $435.0K | - | $157.0K | $345.0K | $172.0K | - |
| Operating Income | ($33.32M) | - | ($8.60M) | ($7.97M) | ($8.05M) | - | ($8.53M) | ($7.70M) | ($8.60M) | - |
| Interest Expense | $73.0K | - | $17.0K | $22.0K | $97.0K | - | $165.0K | $190.0K | $206.0K | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($33.41M) | - | ($8.67M) | ($6.14M) | ($8.14M) | - | ($8.69M) | ($7.89M) | ($8.69M) | - |
| EPS - Basic | ($7.86) | - | ($0.07) | ($0.14) | - | - | - | - | - | - |
| EPS - Diluted | ($2.73) | - | ($0.11) | ($0.06) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.53M | $11.04M | $17.15M | $22.06M | $26.88M | $35.26M | $43.55M | $10.55M | $18.56M | $6.32M |
| Accounts Receivable | $91.0K | $146.0K | - | $184.0K | $86.0K | $0 | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.72M | $2.12M | $1.55M | $1.68M | $2.66M | $1.88M | $1.97M | $4.81M | $3.26M | $4.36M |
| Current Assets | $15.63M | $11.61M | $18.13M | $23.84M | $28.47M | $35.72M | $44.17M | $11.25M | $19.18M | $6.81M |
| Total Assets | $26.45M | $48.39M | $54.99M | $60.85M | $65.71M | $72.01M | $80.45M | $47.71M | $55.34M | $37.67M |
| Current Liabilities | $9.73M | $11.13M | $11.64M | $11.41M | $14.41M | $14.51M | $13.17M | $16.55M | $20.61M | $16.24M |
| Long-term Debt | - | $0 | $0 | $0 | $204.0K | $812.0K | $1.42M | $888.0K | - | - |
| Total Liabilities | $12.39M | $15.41M | $16.79M | $17.78M | $22.56M | $24.50M | $25.21M | $29.25M | $31.36M | $28.28M |
| Stockholders' Equity | $14.05M | $32.98M | $38.20M | $43.07M | $43.15M | $47.52M | $55.24M | $18.46M | $23.97M | $9.39M |
| Retained Earnings | ($395.52M) | ($362.12M) | ($355.14M) | ($346.48M) | ($340.33M) | ($332.19M) | ($324.09M) | ($315.40M) | ($307.51M) | ($298.82M) |
Cash Flow
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.54M) | - | - | - | ($7.46M) | - | - | - | ($8.44M) | - |
| Investing Cash Flow | ($65.0K) | - | - | - | ($3.24M) | - | - | - | ($1.38M) | - |
| Financing Cash Flow | $11.09M | - | - | - | $2.31M | - | - | - | $22.07M | - |
| CapEx | $65.0K | - | - | - | $3.24M | - | - | - | $1.38M | - |
| Free Cash Flow | ($8.61M) | - | - | - | ($10.70M) | - | - | - | ($9.83M) | - |
Ratios
| Metric | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 34.8% | - | -34.9% | - | - | - | - | - | - | - |
| Operating margin | -25240.9% | - | -3410.7% | - | - | - | - | - | - | - |
| EBITDA margin | -25051.5% | - | -3212.3% | - | - | - | - | - | - | - |
| Net margin | -25309.8% | - | -3439.7% | - | - | - | - | - | - | - |
| Free cash flow margin | -6518.9% | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.26 | - | - | - | 1.31 | - | - | - | 1.13 | - |
| R&D / Revenue | 3394.7% | - | 2375.0% | - | - | - | - | - | - | - |
| SG&A / Revenue | 2228.8% | - | 1000.8% | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -126.3% | - | -15.8% | -10.1% | -12.4% | - | -10.8% | -16.5% | -15.7% | - |
| Return on equity | -237.7% | - | -22.7% | -14.3% | -18.9% | - | -15.7% | -42.8% | -36.2% | - |
| Return on invested capital | - | - | -17.8% | -14.6% | -14.7% | - | -11.9% | -31.4% | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.61 | 1.04 | 1.56 | 2.09 | 1.98 | 2.46 | 3.35 | 0.68 | 0.93 | 0.42 |
| Quick ratio | 1.61 | 1.04 | 1.56 | 2.09 | 1.98 | 2.46 | 3.35 | 0.68 | 0.93 | 0.42 |
| Cash ratio | 1.39 | 0.99 | 1.47 | 1.93 | 1.87 | 2.43 | 3.31 | 0.64 | 0.90 | 0.39 |
| Leverage | ||||||||||
| Debt / Equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.05 | - | - |
| Debt / Assets | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.02 | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -456.4x | - | -505.6x | -362.4x | -83.0x | - | -51.7x | -40.5x | -41.7x | - |
| Equity multiplier | 1.88 | 1.47 | 1.44 | 1.41 | 1.52 | 1.52 | 1.46 | 2.58 | 2.31 | 4.01 |
| Liabilities / Assets | 0.47 | 0.32 | 0.31 | 0.29 | 0.34 | 0.34 | 0.31 | 0.61 | 0.57 | 0.75 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 252d | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 15788d | - | 1665d | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -314.0% | - | -0.8% | -3.6% | 6.4% | - | 10.8% | 18.2% | 9.4% | - |
| Net income growth (YoY) | -310.3% | - | 0.2% | 22.2% | 6.3% | - | 11.9% | 15.7% | 7.8% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 19.5% | - | - | - | -8.8% | - | - | - | 14.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -67.4% | -30.6% | -30.8% | 133.2% | 80.0% | 405.9% | 432.3% | -2.9% | 148.4% | -49.8% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Zosano Pharma Corp against the 5 most active filers in the same SIC group.